Hartman spent 22 years with Stryker, during which he served as the president of the instruments division for 9 years, preceding his 4 year reign as CFO. Hartman left the company in October 2012 after a stint as the company’s interim CEO after former chief Stephen MacMillan was ousted in February of the same year.
"Curt has extraordinary medical device leadership experience, as well as a strategic and entrepreneurial mindset that has consistently delivered market leading results," Veran president and CEO Jason Pesterfield said in prepared remarks."We are delighted that he is joining Veran’s Board of Directors. We are excited to attract the caliber of expertise that Curt Hartman brings to the table and view this as a strong indication of the potential for Veran’s success now and in the future."
Hartman also serves as member of the board for Devicor Medical Products.
InVivo founders, PixarBio starting biotech venture
PixarBio is launching a biotech venture with InVivo Therapeutics (OTC:NVIV) founders Frank Reynolds and Dr. Robert Langer. The group, which will also include Dr. Randy Holmes-Farley and Katrin Holzhaus, will focus on researching and developing long term-personalized drug delivery systems for Parkinson’s Disease.
InVivo appoints former Repligen exec as business development VP
InVivo Therapeutics (OTC:NVIV) appointed Christopher McNulty as its new vice president of business development. McNulty joins the company from Repligen Corp., where he served as the senior director of business development.
Medtronic ex-VP joins EBS Technologies board
EBS Technologies named Karl Schweitzer to its board of directors. Schweitzer was formerly the vice president and general manager of Neuromodulation for Medtronic (NYSE:MDT).
Histogenics names Dendreon Corp. CEO to board
Histogenics added Dendreon CEO & president John Johnson to its board of directors. Johnson has previously worked with Johnson & Johnson (NYSE:JNJ), Eli Lilly (NYSE:LLY), and Savient Pharmaceuticals.